Guidelines for Exercise in Multiple Sclerosis (GEMS) for Multiple Sclerosis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Illinois at Chicago, Chicago, IL
Multiple Sclerosis+1 More
Guidelines for Exercise in Multiple Sclerosis (GEMS) - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if a remotely-delivered, racially-tailored exercise training program can improve walking dysfunction, symptoms, and health-related quality of life for African-Americans with MS who live in rural areas. The FDA has approved the use of the Guidelines for Exercise in Multiple Sclerosis (GEMS) treatment for multiple sclerosis. The treatment is available online. This is the first time the FDA has approved the use of this treatment for multiple sclerosis.

Eligible Conditions

  • Multiple Sclerosis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Changes in walking scores from Baseline, 4-months, and 8-months.

Month 4
Anxiety
Month 4
Depressive Symptoms
Month 8
Disability
Month 4
Exercise Behavior
Month 4
Fatigue Severity
Month 4
Health-related Quality of Life (HRQOL)
Changes in walking scores from Baseline, 4-months, and 8-months.
Walking Dysfunction

Trial Safety

Trial Design

2 Treatment Groups

Guidelines for Exercise in Multiple Sclerosis (GEMS)
1 of 2
FLEX Stretching and Toning Program
1 of 2
Experimental Treatment
Non-Treatment Group

100 Total Participants · 2 Treatment Groups

Primary Treatment: Guidelines for Exercise in Multiple Sclerosis (GEMS) · Has Placebo Group · N/A

Guidelines for Exercise in Multiple Sclerosis (GEMS)
Behavioral
Experimental Group · 1 Intervention: Guidelines for Exercise in Multiple Sclerosis (GEMS) · Intervention Types: Behavioral
FLEX Stretching and Toning Program
Behavioral
ShamComparator Group · 1 Intervention: FLEX Stretching and Toning Program · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: changes in walking scores from baseline, 4-months, and 8-months.
Closest Location: University of Illinois at Chicago · Chicago, IL
Photo of Chicago 1Photo of Chicago 2Photo of Chicago 3
2000First Recorded Clinical Trial
5 TrialsResearching Multiple Sclerosis
264 CompletedClinical Trials

Who is running the clinical trial?

Bristol-Myers Squibb FoundationUNKNOWN
2 Previous Clinical Trials
320 Total Patients Enrolled
University of Alabama at BirminghamOTHER
1,403 Previous Clinical Trials
2,211,009 Total Patients Enrolled
34 Trials studying Multiple Sclerosis
5,026 Patients Enrolled for Multiple Sclerosis
University of Illinois at ChicagoLead Sponsor
519 Previous Clinical Trials
1,502,429 Total Patients Enrolled
5 Trials studying Multiple Sclerosis
909 Patients Enrolled for Multiple Sclerosis
Robert W Motl, PhDPrincipal InvestigatorUniversity of Illinois at Chicago
7 Previous Clinical Trials
771 Total Patients Enrolled
7 Trials studying Multiple Sclerosis
771 Patients Enrolled for Multiple Sclerosis

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have English as your primary language.
You are at least 18 years old.
You are not meeting current physical activity guidelines based on GLTEQ.
You have mild-moderate ambulatory disability.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.